Nocdurna Generic: When Will Generic Desmopressin Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Nocdurna Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? April 2030 About 3.5 years away Why then?
- Has the FDA approved a generic? July 2005 5 companies approved
- When does the last patent end? April 2030 4 patents listed with the FDA
- Can you buy a generic today? Yes 13 companies list one
It already is. A generic desmopressin acetate is listed for sale by 13 companies, so ask your pharmacy whether it can fill your prescription with one.
Why April 2030?
It is when Nocdurna’s patent 9,974,826 ends. That patent covers a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Nocdurna, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Nocdurna by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2018 June 2018 FDA Orange Book
- Patents listed 4 last runs to April 2030 FDA Orange Book
- Generics FDA-approved 5 companies, the first approved July 2005 FDA Orange Book
Nocdurna’s Road to a Generic
Nocdurna has had the market to itself since the FDA approved it in June 2018 (Ferring Pharmaceuticals Inc). Its 4 listed patents run to April 2030.
The first generic of Nocdurna is expected in April 2030.
Why that month: patent 9,974,826, on a way of using it, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Nocdurna Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Nocdurna’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 9,974,826, which ends in April 2030, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 10,137,167 | A way of using it (U-2327) | May 2029 | Active |
| 11,020,448 | A way of using it (U-2327) | May 2029 | Active |
| 11,963,995 | A way of using it (U-2327) | May 2029 | Active |
| 9,974,826 Sets the expected month of generic availability | A way of using it (U-2326, U-2327) | April 2030 | Active |
Source: FDA Orange Book, application 022517. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Desmopressin Acetate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No application count is on record for Nocdurna, but the FDA has already approved 5 companies (step 2), and every approval starts with an application.
Approved by the FDA
The FDA has approved generic versions from 5 companies, the first in July 2005. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic desmopressin acetate is listed for sale by 13 companies. Ask your pharmacy whether it can fill your prescription with it.
Actavis Pharma, Inc., American Health Packaging, Apotex Corp., Aurobindo Pharma Limited, BluePoint Laboratories, Bryant Ranch Prepack and 7 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Apotex Inc | March 2006 | 0.1MG, 0.2MG | AB |
| Heritage Pharma Labs Inc | May 2017 | 0.1MG, 0.2MG | AB |
| Abhai LLC | January 2019 | 0.1MG, 0.2MG | AB |
| Novast Laboratories Ltd | June 2019 | 0.1MG, 0.2MG | AB |
| Aurobindo Pharma Ltd | March 2024 | 0.1MG, 0.2MG | AB |
| Actavis Laboratories Fl Inc discontinued | July 2005 | 0.1MG, 0.2MG | – |
| Impax Laboratories Inc discontinued | January 2006 | 0.1MG, 0.2MG | – |
| Natco Pharma USA LLC discontinued | June 2014 | 0.1MG, 0.2MG | – |
| Glenmark Pharmaceuticals Ltd discontinued | May 2015 | 0.1MG, 0.2MG | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Nocdurna Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Nocdurna, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
Nocdurna Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 0.0277MG | Tablet | Sublingual | June 2018 | Discontinued reference product |
| 0.0553MG | Tablet | Sublingual | June 2018 | Discontinued reference product |
Source: FDA Orange Book, Ferring Pharmaceuticals Inc. Listed for sale today by Antares Pharma, Inc. and Ferring Pharmaceuticals Inc. (FDA NDC Directory).
Nocdurna NDC Codes and Packages
Each Nocdurna package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 54436-0325-30 | 27.7 ug tablet | carton of 3 blister packs of 10 tablets | Antares Pharma, Inc. |
| 54436-0350-30 | 55.3 ug tablet | carton of 3 blister packs of 10 tablets | Antares Pharma, Inc. |
| 55566-5070-01 | 55.3 ug tablet | carton of 3 blister packs of 10 tablets | Ferring Pharmaceuticals Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Nocdurna’s own FDA approval (NDA 22517) are listed, never a generic. Some codes belong to companies that repackage Nocdurna: it is the same medicine in a different package.
What a Generic Nocdurna Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Nocdurna
Is there a generic for Nocdurna right now?
Yes. The FDA NDC Directory lists a generic desmopressin acetate from 13 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Nocdurna go generic?
It already has. The FDA NDC Directory lists a generic desmopressin acetate from 13 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic desmopressin acetate be the same as Nocdurna?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. The FDA has already approved 5 companies to make a generic, and how many of them launch decides how far the price falls.
Has the FDA approved a generic Nocdurna?
Yes. The FDA Orange Book lists approved generic versions from 5 companies, the first approved in July 2005: Apotex Inc, Heritage Pharma Labs Inc, Abhai LLC, Novast Laboratories Ltd and 1 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Nocdurna patent expire?
The FDA Orange Book lists 4 patents for Nocdurna; the last runs to April 2030. The one behind the expected month is patent 9,974,826, which ends in April 2030. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (April 2030) weighs all of that.
Changes to This Projection
- First generic expected April 2030 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- LikmezMetronidazole2030 to 2031
- TerlivazTerlipressin AcetateMarch 2030
- YcanthCantharidinJanuary 2031
- PifeltroDoravirineAugust 2032
- BrekiyaDihydroergotamine MesylateAugust 2039
- FinaceaAzelaic AcidTBD no date yet
About Nocdurna
- Generic name desmopressin acetate
- How it is taken By mouth
- Company Ferring Pharmaceuticals Inc
- More drugs Brand-name drugs starting with N
- Have a question? A pharmacist answers, free. Ask about Nocdurna
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.